Unrestricted use of endeavor resolute zotarolimus-eluting stent in daily clinical practice: A prospective registry

Journal of Invasive Cardiology

Volumn 24, Issue 6, 2012, Pages 251-255

  Galasso, Gennaro ^a   Piccolo, Raffaele ^a   Cassese, Salvatore ^a   Esposito, Giovanni ^a   Cirillo, Plinio ^a   Leosco, Dario ^a   Rapacciuolo, Antonio ^a   Sirico, Domenico ^a   De Biase, Chiara ^a   Niglio, Tullio ^a   Piscione, Federico ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDEAVOR RESOLUTE ZOTAROLIMUS-ELUTING STENT; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BYPASS SURGERY; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; CORONARY BIFURCATION LESION; DEATH; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TARGET VESSEL REVASCULARIZATION; THROMBUS;

ANGIOPLASTY, BALLOON, CORONARY; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; OFF-LABEL USE; PROSPECTIVE STUDIES; PROSTHESIS FAILURE; REGISTRIES; RISK ASSESSMENT; SIROLIMUS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84862871796     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119(25):3198-3206.
2. Piscione F, Piccolo R, Cassese S, et al. Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison. EuroIntervention. 2010;5(7):853-860.
3. Piscione F, Piccolo R, Cassese S, Galasso G, Chiariello M. Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials. Catheter Cardiovasc Interv. 2009;74(2):323-332.
4. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007;297(18):1992-2000. (Pubitemid 46740351)
5. Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358(4):342-352. (Pubitemid 351159233)
6. Pinto Slottow TL, Waksman R. Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. Catheter Cardiovasc Interv. 2007;69(7):1064-1074. (Pubitemid 46900788)
7. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297(18):2001-2009. (Pubitemid 46740352)
8. Brodie BR, Stuckey T, Downey W, et al. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group. J Am Coll Cardiol. 2008;1(4):405-414.
9. Meredith IT, Worthley S, Whitbourn R, et al. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention. 2007;3(1):50-53.
10. Udipi K, Melder RJ, Chen M, et al. The next generation Endeavor Resolute stent: role of the BioLinx Polymer System. EuroIntervention. 2007;3(1):137-139.
11. Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol. 2010;56(10 SUPPL.):S43-S78.
12. Pinto Slottow TL, Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the Endeavor zotarolimus-eluting coronary stent. Circulation. 2008;117(12):1603-1608. (Pubitemid 351440648)
13. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351. (Pubitemid 46685903)
14. Meredith IT, Worthley S, Whitbourn R, et al. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. J Am Coll Cardiol. 2009;2(10):977-985.
15. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2):136-146.
16. Silber S, Windecker S, Vranckx P, Serruys PW. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet. 2011;377(9773):1241-1247.
17. Costa JR Jr, Sousa A, Moreira AC, et al. Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (drug-eluting stents in the real world)-late registry. J Am Coll Cardiol. 2010;3(1):12-18.
18. Raber L, Juni P, Loffel L, et al. Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation. J Am Coll Cardiol. 2010;55(12):1178-1188.
19. Lotan C, Meredith IT, Mauri L, Liu M, Rothman MT. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. J Am Coll Cardiol. 2009;2(12):1227-1235.
20. Uchida T, Popma J, Stone GW, et al. The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of oculostenotic reintervention in patients with intermediate lesions. J Am Coll Cardiol. 2010;3(4):403-411.